TITLE

New acute treatments for headache

AUTHOR(S)
Rapoport, Alan M.
PUB. DATE
June 2010
SOURCE
Neurological Sciences;Jun2010, Vol. 31, p129
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Although we have several acute care medications for the treatment of migraine, we are always looking for new medications to treat our patients. Patients often say that their headaches are not under optimal control and would be happy to try another medication. Patients look for faster onset of relief, more complete relief, no recurrent headache and no adverse events. This article will cover some new and some anticipated acute care products, CGRP antagonists, sumatriptan by iontophoretic patch, sumatriptan by needle-free injections, DHE by oral inhalation and diclofenac potassium in a sachet. Botulinum toxin therapy, although a preventive measure, will be mentioned at the end.
ACCESSION #
50423042

 

Related Articles

  • Clinical Profile of Botulinum Toxin A in Patients with Chronic Headaches and Cervical Dystonia: A Prospective, Open-Label, Longitudinal Study Conducted in a Naturalistic Clinical Practice Setting. Dowson, Andrew J; Kilminster, Shaun G; Salt, Rebecca // Drugs in R&D;2008, Vol. 9 Issue 3, p147 

    BACKGROUND AND OBJECTIVES: Some evidence for the efficacy of botulinum toxin A as a preventive treatment for chronic primary headaches has been reported in randomized, controlled clinical studies. This study investigated the clinical profile of botulinum toxin A in a naturalistic clinical...

  • OnabotulinumtoxinA (BOTOX®): A Guide to Its Use in Preventing Headaches in Adults with Chronic Migraine. Lyseng-Williamson, Katherine A.; Frampton, James E. // CNS Drugs;2012, Vol. 26 Issue 8, p717 

    Intramuscular onabotulinumtoxinA (onaBoNTA; BOTOX®) is indicated for headache prophylaxis in adults with chronic migraine. According to pooled results from two large trials, treatment with up to five cycles of ona-BoNTA (155-195 units/cycle) at 12-week intervals was effective in reducing...

  • Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 Ã… resolution. Hanson, Michael A.; Stevens, Raymond C. // Nature Structural Biology;Aug2000, Vol. 7 Issue 8, p687 

    Botulinum neurotoxin serotype B is a zinc protease that disrupts neurotransmitter release by cleaving synaptobrevin-II (Sb2), one of three SNARE proteins involved in neuronal synaptic vesicle fusion. The three-dimensional crystal structure of the apo botulinum neurotoxin serotype B catalytic...

  • Uses of botulinum toxin injection in medicine today. Munchau, A.; Bhatia, K. P. // BMJ: British Medical Journal (International Edition);01/15/2000, Vol. 320 Issue 7228, p161 

    Discusses the uses of botulinum toxin injection in modern medicine. Mode of action; Rationale for treatment with botulinum neurotoxin; Side effects of the toxin; Indications for treatment.

  • The many faces of botox. Cohen, Sharon; Kallen, Ben // Shape;Jul2004, Vol. 23 Issue 11, p93 

    Reports on various uses of botulinum toxin.

  • Editors' Response to Johnson. Hooper, David C.; Hirsch, Martin S. // Journal of Infectious Diseases;Sep2014, Vol. 210 Issue 6, p993 

    A response from the editor related to articles regarding the purported new botulinum neurotoxin serotype H published in a 2014 issue is presented.

  • A Botulinum Toxin Indication for Pediatric Headache? Merriman, John // Neurology Reviews;Oct2006, Vol. 14 Issue 10, p1 

    The article reports on the importance of botulinum toxin A in treating pediatric headache. Medical doctor Marielle A. Kabbouche stresses that IV dihydroergotamine is more effective if botulinum toxin A will be added to it specially in treating chronic intractable headache. Research found that...

  • Clinical Uses of Botulinum Neurotoxins: Current Indications, Limitations and Future Developments. Sheng Chen // Toxins;Oct2012, Vol. 4 Issue 10, p913 

    Botulinum neurotoxins (BoNTs) cause flaccid paralysis by interfering with vesicle fusion and neurotransmitter release in the neuronal cells. BoNTs are the most widely used therapeutic proteins. BoNT/A was approved by the U.S. FDA to treat strabismus, blepharospam, and hemificial spasm as early...

  • Long-lasting benefits of botulinum toxin type B in Parkinson’s disease-related drooling. Lagalla, Giovanni; Millevolte, Marzia; Capecci, Marianna; Provinciali, Leandro; Ceravolo, Maria Gabriella // Journal of Neurology;Apr2009, Vol. 256 Issue 4, p563 

    To investigate the safety, efficacy and effectiveness of botulinum toxin type-B (BTX-B) injections into the parotid glands to reduce drooling in Parkinson’s disease (PD) subjects. A double-blind, randomised, placebo-controlled study enrolled 36 advanced phase PD subjects who complained of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics